Member Info for Chelsea11

TF - Cleaner is collating a list if you have any insightful questions for the AGM.

I’m not expecting the AGM to carry any significant news. More often than not, they are not a great deal more than a box-ticking exercise (non-specific to Scancell). I suspect the news we are waiting for will come at a later date and imo that will not mean it’s because they didn’t want to break bad news at an AGM.

I’ve already checked the bus timetable.

Your horse is an awful lot higher than mine Trotsky. You need a stepladder to get on it.

Stop being a last word merchant. It’s making you look quite foolish.

Sempre busy showcasing / networking. New product too.

Converting conversation to future deals hopefully.

https://www.thesempregroup.com/events/

Maybe an RNS here inside what is left of Q4, will overtake the Evaxion convo and make it “eat my shorts”.

For those here wedded to AI……..

It is not advisable to literally eat shorts, as they are made of fabric and are harmful if consumed.

GLA

Bravado? No.

Total transparency.

Sure Trotsky, my confidence is higher than yours and I’m backing with hard cash, not words on a BB.

That’s it. Time will tell.

Couerdelion - not sure if your 07:39 was directed at me but if it was, I would agree that averaging down isn’t going to win out in all cases.

However, here I am backing that action, against taking no action.

Black and white. No flannel.

So Trotsky, cutting through the whole exchange, I’ve averaged down (to 57p) and you’ve chosen not to.

Guess in the coming months we will see whos investment strategy comes out on top.

Ok well if you’re not averaging down, your personal & candid assessment of the prospects here must mean you’re happy to wait an extremely long time for the SP to recover.

Trotsky - I made a mistake here when passing up several opportunities to sell around a quid. You can’t and won’t admit it’s exactly the same for you as you are very clearly the kind of person where if something doesn’t go your way, it will ALWAYS be someone else’s fault and never, ever down to your own decision making. I’ll always own my investment decisions but perhaps that’s down to my personal integrity.

Btw, you now have the chance to average down and I’ve done exactly that ie. put my money where my mouth is. Will you do the same and show some faith in your investment, or simply carry on bleating doom?

18th June, “Terminal Decline” and as recently as 9th October, “dim prospect”.

But of course in your head you didn’t post either Trotsky, did you!

Seems honesty just isn’t one of your strong points.

“Terminal decline” and a “dim prospect”

Apparently.

Well done to those who ignored and bought in circa 40p.

The SPs of plenty of other companies doing well are also depressed. Like here, they are potentially buying opportunities, assuming the market as a whole doesn’t experience a crash. As I posted previously, I don’t expect a big short term rise here and until good numbers start flowing from geographical expansion, principally North America. Currently revenue is tiny but they are working on that and I hope for better news in Q1 2026.

Maybe elaborate on why you believe the SP suggests a company with very serious problems ahead? Tangible reasoning?

“This sp suggests a company with very serious problems ahead”

Utter nonsense.

Would describe as steady as she goes. Need much more from North America in this financial year. Maybe the AGM Statement in December will reveal more on that, if not the Interims in Feb 26.

For those here who seem unable to see the positive benefits of continuing conference attendance.

Here is an extract from the 22/07 RNS:

Dr Heather Shaw, lead for the Medical Oncology Skin Cancer Service at University College London Hospital, London and principal investigator of the SCOPE trial, said: "The addition of SCIB1 or iSCIB1+ to standard-of-care checkpoint inhibitors has demonstrated extremely exciting early signals, including improved overall response rates and progression-free survival to date, without a meaningful increase in treatment-related toxicity. These findings highlight the real potential for a significant clinical benefit for patients with advanced melanoma, where there is an unmet need. As the progression-free survival and overall survival data matures, expediting the planned registrational randomised controlled trial will be critical. This study will have the potential to redefine current treatment paradigms for a disease that remains challenging for many patients."

It’s very clear isn’t it, that as more data rolls in, the stronger the message becomes, the harder it is to ignore and the more likely it is that someone will pull the trigger.

Industry Conferences are critical showcasing & networking opportunities and short sighted to think otherwise. Why else would all the heavyweights attend.

😂

Couerdelion - Trotsky is the classic pompous know-all, so you’re bound to get a response. Most likely one that completely skirts round the point you make.